Acquirer: GIC Pte. Ltd. (Singapore)
Acquired: Biomat USA, Inc. (U.S.)
Value: US$1 billion
On June 30, 2021, Grifols S.A., a Spanish pharmaceutical and chemical company that is a leading producer of blood plasma-based products, announced that “it has signed a corporate transaction by means of which GIC, the sovereign wealth fund of Singapore, have entered into a definitive agreement under which GIC will invest approx. US$1 Bn in Grifols’ wholly-owned US subsidiary Biomat USA, Inc.,” and “will acquire a minority stake in Biomat, in the form of newly issued preferred non-voting stock.” (Grifols, S.A., Form 6-K, June 30, 2021, SEC Filing.) Biomat USA, Inc., “holds a plasma collection business with 296 plasma collection centers throughout the territory of the United States.” (Id.) On November 17, 2021, Grifols announced that “the regulatory authorizations to which the transaction was subject, among others the one from . . . (CFIUS), have already been obtained.” (Grifols, S.A., Form 6-K, Nov. 17, 2021, SEC Filing)
Please contact Peter Alfano with any questions.